Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cobolimab
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cobolimab is a therapeutic antibody developed for immuno-oncology through a collaboration between AnaptysBio and Tesaro, which was later acquired by GlaxoSmithKline. It targets T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). AnaptysBio was responsible for the discovery and early preclinical development of the antibody, while GlaxoSmithKline is responsible for subsequent preclinical, clinical, regulatory, and commercial development.
- Other names
- cobolimabTSR-022TSR022TSR 022WBP-296AWBP296AWBP 296A
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on cobolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cobolimab.